These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 75485)

  • 21. [Effects of high doses of exogenous interferon in systemic lupus erythematosus].
    Savinov VA; Alekberova ZS; Barinskiĭ IF; Bulanova TD; Kuznetsov VP
    Ter Arkh; 1981; 53(7):118-21. PubMed ID: 6170126
    [No Abstract]   [Full Text] [Related]  

  • 22. Serum interferon level and (2'-5')oligoadenylate synthetase activity in lymphocytes during clinical interferon application.
    Lodemann E; Nitsche EM; Lang MH; Gerein V; Altmeyer P; Holzmann H; Kornhuber B
    J Interferon Res; 1985; 5(4):621-8. PubMed ID: 2418131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of tissue viral resistance in chickens following administration of interferon inducers.
    Finkelstein MS
    J Immunol; 1972 Jun; 108(6):1506-16. PubMed ID: 4337965
    [No Abstract]   [Full Text] [Related]  

  • 24. LEUKOCYTES AND INTERFERON IN THE HOST RESPONSE TO VIRAL INFECTIONS. I. MOUSE LEUKOCYTES AND LEUKOCYTE-PRODUCED INTERFERON IN VACCINIA VIRUS INFECTION IN VITRO.
    GLASGOW LA
    J Exp Med; 1965 Jun; 121(6):1001-18. PubMed ID: 14319399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interferon in the treatment of ovarian cancer.
    Welander CE
    Semin Oncol; 1988 Oct; 15(5 Suppl 5):26-9. PubMed ID: 2461594
    [No Abstract]   [Full Text] [Related]  

  • 26. [The interferon status in recurrent genital herpes].
    Malinovskaia VV; Temicheva EV; Panasiuk AF; Semenova TB
    Vopr Virusol; 1991; 36(3):254-6. PubMed ID: 1716394
    [No Abstract]   [Full Text] [Related]  

  • 27. Physico-chemical characteristics of interferons induced by human adenovirus in chick fibroblasts and leucocytes.
    Taródi B; Pusztai R; Berencsi K
    Acta Virol; 1975 Sep; 19(5):393-400. PubMed ID: 241243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological aspects of clinical stage I/II trials with human beta interferon in children.
    Treuner J; Dannecker G; Joester KE; Hettinger A; Niethammer D
    J Interferon Res; 1981; 1(3):373-80. PubMed ID: 6180069
    [No Abstract]   [Full Text] [Related]  

  • 29. Administration of human leukocyte interferon in herpes zoster. I. Safety, circulating, antiviral activity, and host responses to infection.
    Jordan GW; Fried RP; Merigan TC
    J Infect Dis; 1974 Jul; 130(1):56-62. PubMed ID: 4601181
    [No Abstract]   [Full Text] [Related]  

  • 30. [Simple method of determining the antiproliferative activity of human interferons].
    Aspetov RD; Shaĭkhinova TB; Novokhatskiĭ AS; Shuratov IKh
    Antibiot Med Biotekhnol; 1985 Mar; 30(3):204-8. PubMed ID: 2409914
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Interferon: facts and hopes. II. Interferon treatment].
    Dmoszyńska-Giannopoulou A; Rupniewska ZM
    Pol Arch Med Wewn; 1981 Oct; 66(4):307-11. PubMed ID: 6174954
    [No Abstract]   [Full Text] [Related]  

  • 32. Initial interaction of human fibroblast and leukocyte interferons with FS-4 fibroblasts.
    Gardner LJ; Vilcek J
    J Gen Virol; 1979 Jul; 44(1):161-8. PubMed ID: 227987
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interferon clearance rate decreased after repeated injections.
    Nuwer MR; De Clercq E; Merigan TC
    J Gen Virol; 1971 Aug; 12(2):191-4. PubMed ID: 4330791
    [No Abstract]   [Full Text] [Related]  

  • 34. Interferons and interferon inducers: development of clinical usefulness and therapeutic promise.
    Pollard RB
    Drugs; 1982; 23(1-2):37-55. PubMed ID: 6173188
    [No Abstract]   [Full Text] [Related]  

  • 35. [Stimulation of interferon formation in animals and humans and the obtainment of donor plasma containing interferon for clinical parenteral use].
    Skurkovich SV; Sabashvili MK
    Probl Gematol Pereliv Krovi; 1971 Jun; 16(6):11-4. PubMed ID: 5119056
    [No Abstract]   [Full Text] [Related]  

  • 36. [Change in interferon status in patients with acute viral hepatitis during intramuscular and rectal administration of genetically engineered alpha-2-interferon].
    Malinovskaia VV; Neumoina MV; Budanov SV
    Vopr Virusol; 1994; 39(6):269-72. PubMed ID: 7536374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interferon: pharmacokinetics and toxicity.
    Scott GM
    Philos Trans R Soc Lond B Biol Sci; 1982 Sep; 299(1094):91-107. PubMed ID: 6183699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon skin reactivity and pyrexial reactions.
    Scott GM; Butler JK; Cartwright T; Richards BM; Kingham JG; Wright R; Tyrrell DA
    Lancet; 1977 Aug; 2(8034):402-3. PubMed ID: 70611
    [No Abstract]   [Full Text] [Related]  

  • 39. [Genesis of interferon in healthy nonpregnant women and in physiological pregnancy].
    Bizhan UI; Shchelykalina LA; Stoianov NG
    Akush Ginekol (Mosk); 1978 Feb; (2):17-20. PubMed ID: 637226
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical and laboratory investigations on man: systemic administration of potent interferon to man.
    Strander H; Cantell K; Carlström G; Jakobsson PA
    J Natl Cancer Inst; 1973 Sep; 51(3):733-42. PubMed ID: 4355215
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.